Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 4/20 | 0.74 |
| ▸ | ALOX5 | P09917 | 9/20 | 0.72 |
| ▸ | AKR1B10 | O60218 | 4/20 | 0.65 |
| ▸ | AKR1B1 | P15121 | 4/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.65 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | GMNN | O75496 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | EGFR | P00533 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | ESR1 | P03372 | 1/20 | 0.65 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.65 |
| ▸ | APP | P05067 | 1/20 | 0.65 |
| ▸ | LCK | P06239 | 1/20 | 0.65 |
| ▸ | FYN | P06241 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15378926 | 1.00 | TTR (0.74) | TTRALOX5AKR1B10AKR1B1CYP3A4 | |
| SCHEMBL15384911 | 0.93 | ALOX5 (0.66) | TTRALOX5AKR1B10AKR1B1CYP3A4 | |
| SCHEMBL15384916 | 0.91 | TTR (0.71) | TTRALOX5AKR1B10AKR1B1CYP3A4 | |
| SCHEMBL8034404 | 0.90 | ALOX5 (0.79) | TTRALOX5KDM4EALDH1A1MAPT | |
| SCHEMBL15384910 | 0.88 | CA12 (0.67) | TTRALOX5AKR1B10AKR1B1KDM4E | |
| SCHEMBL14113938 | 0.85 | TTR (1.00) | TTRALOX5AKR1B10AKR1B1CYP3A4 | |
| SCHEMBL15384086 | 0.85 | TTR (0.67) | TTRALOX5AKR1B10AKR1B1CYP3A4 | |
| SCHEMBL15884145 | 0.84 | ALOX5 (1.00) | TTRALOX5AKR1B10AKR1B1KDM4E | |
| SCHEMBL24617861 | 0.83 | ALOX5 (0.74) | ALOX5KDM4EALDH1A1APPMAPT | |
| SCHEMBL28181780 | 0.83 | ALOX5 (0.72) | TTRALOX5KDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2629766-B1 | COMBINATION THERAPY | Chemigen (US) | 2017-02-22 | — | — | EP | disclosed |
| US-9532967-B2 | Use of phenethyl caffeate derivatives in the preparation of a medicament against tumor angiogenesis | LIU JUNYI (CN) | 2017-01-03 | — | — | US | disclosed |
| US-9040579-B2 | Combination therapy using coenzyme Q10 and a caffeic acid-derived ester | Chemigen (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040579-B2 | Combination therapy using coenzyme Q10 and a caffeic acid-derived ester | Chemigen (US) | 2015-05-26 | — | — | US | disclosed |
| US-8993621-B2 | Caffeic acid derivatives and their use in improving neuronal cell viability | CHEMIGEN, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8993621-B2 | Caffeic acid derivatives and their use in improving neuronal cell viability | CHEMIGEN, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20130303611-A1 | USE OF PHENETHYL CAFFEATE DERIVATIVES IN THE PREPARATION OF A MEDICAMENT AGAINST TUMOR ANGIOGENESIS | LIU JUNYI (CN) | 2013-11-14 | — | — | US | disclosed |
| US-20130303611-A1 | USE OF PHENETHYL CAFFEATE DERIVATIVES IN THE PREPARATION OF A MEDICAMENT AGAINST TUMOR ANGIOGENESIS | LIU JUNYI (CN) | 2013-11-14 | — | — | US | disclosed |
| US-20120129931-A1 | CAFFEIC ACID DERIVATIVES AND THEIR USE IN IMPROVING NEURONAL CELL VIABILITY | Chemigen (US) | 2012-05-24 | — | — | US | disclosed |
| WO-2012068038-A2 | CAFFEIC ACID DERIVATIVES AND THEIR USE IN IMPROVING NEURONAL CELL VIABILITY | Chemigen (US) | 2012-05-24 | — | — | WO | disclosed |
| US-20120129931-A1 | CAFFEIC ACID DERIVATIVES AND THEIR USE IN IMPROVING NEURONAL CELL VIABILITY | Chemigen (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120100122-A1 | COMBINATION THERAPY | Chemigen (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120100122-A1 | COMBINATION THERAPY | Chemigen (US) | 2012-04-26 | — | — | US | disclosed |
| WO-2012054446-A2 | COMBINATION THERAPY | Chemigen (US) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303611-A1 | USE OF PHENETHYL CAFFEATE DERIVATIVES IN THE PREPARATION OF A MEDICAMENT AGAINST TUMOR ANGIOGENESIS | NR4A3, CBR3, NCOA3 | TTR 4119/4885ALOX5 560/4885AKR1B10 1990/4885 |
| US-20120129931-A1 | CAFFEIC ACID DERIVATIVES AND THEIR USE IN IMPROVING NEURONAL CELL VIABILITY | CCAR2, BDNF, CASP3 | TTR 4828/4885ALOX5 1341/4885AKR1B10 4586/4885 |
| US-20120100122-A1 | COMBINATION THERAPY | SLC25A20, TFAM, NDUFAB1 | TTR 341/4885ALOX5 1085/4885AKR1B10 1036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.